Immuron Limited ( (AU:IMC) ) has issued an update.
Immuron Limited announced the cessation of 285,741 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation may impact the company’s capital structure and could have implications for stakeholders, reflecting challenges in meeting performance conditions.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutic products for the treatment of immune-mediated diseases.
YTD Price Performance: -40.0%
Average Trading Volume: 31,579
Technical Sentiment Signal: Strong Buy
Current Market Cap: €7.83M
For detailed information about IMC stock, go to TipRanks’ Stock Analysis page.